| Literature DB >> 17959600 |
Gawain McColl1, David W Killilea2, Alan E Hubbard3, Maithili C Vantipalli4, Simon Melov4, Gordon J Lithgow4.
Abstract
Lithium (Li(+)) has been used to treat mood affect disorders, including bipolar, for decades. This drug is neuroprotective and has several identified molecular targets. However, it has a narrow therapeutic range and the one or more underlying mechanisms of its therapeutic action are not understood. Here we describe a pharmacogenetic study of Li(+) in the nematode Caenorhabditis elegans. Exposure to Li(+) at clinically relevant concentrations throughout adulthood increases survival during normal aging (up to 46% median increase). Longevity is extended via a novel mechanism with altered expression of genes encoding nucleosome-associated functions. Li(+) treatment results in reduced expression of the worm ortholog of LSD-1 (T08D10.2), a histone demethylase; knockdown by RNA interference of T08D10.2 is sufficient to extend longevity ( approximately 25% median increase), suggesting Li(+) regulates survival by modulating histone methylation and chromatin structure.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17959600 PMCID: PMC2739662 DOI: 10.1074/jbc.M705028200
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157